For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Rizatriptan - Migraine (acute)
PAD Profile : Rizatriptan - Migraine (acute) Important
Traffic Light Status
Status 1 of 3.
- Tablets
Status 2 of 3.
- Oro-dispersible
Status 3 of 3.
Guidelines
No guidelines returned.
Other Drugs
- Naratriptan hydrochloride
- Sumatriptan succinate
- Zolmitriptan
- Frovatriptan
- Almotriptan
- Eletriptan
- Melatonin
- Rimegepant
- Analgesics with anti-emetics
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
UPDATED: The PCN recommends that sumatriptan, zolmitriptan, rizatriptan and naratriptan should be considered as first line triptans where clinically appropriate and should be prescribed generically.
Zolmitriptan/ Rizatriptan orodispersible tablets should be considered as a suitable first line treatment for patients when there are difficulties in swallowing the solid dose formulations or the patient has difficulties with nausea and vomiting.
Rizatriptan oral lyophilisates (Maxalt Melt) should not be prescribed. Please see the policy statement below for further information